Deutsche Bank Starts Jazz Pharmaceuticals (JAZZ) at Buy

Deutsche Bank initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and a price target of $176.00.

Analyst Gregg Gilbert said, "We expect Jazz’s current business to drive continued strong revenue and earnings growth over the next few years, which sets the company apart from many of its peers in the Specialty Pharma group that rely on deals for growth. Led by a capable and thoughtful management team, we expect the company to remain focused on high-growth, durable products for specialty indications that can be marketed with a narrow sales force. We note that its tax structure and growth profile could make Jazz a potential target by companies seeking a tax inversion and growth injection."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $146.21 yesterday.

You May Also Be Interested In

• Stifel Starts Tower Semiconductor (TSEM) at Buy, Top Pick
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
• Raymond James Resumes Ally Financial (ALLY) at Strong Buy